Results 111 to 120 of about 3,371 (214)

Case Report: Four cases for cariprazine and alcohol use disorder. [PDF]

Front Psychiatry
Vicentic S.
europepmc   +1 more source

Folyadékfázisú, heterogén katalitikus hidrogénezések [PDF]

, 2015
Hegedűs, László
core  

Unexpected resolution of clozapine-induced obsessive-compulsive symptoms with cariprazine augmentation: a case report. [PDF]

BMC Psychiatry
Rammouz I, El Oumary O, Hamri S, Akebour K, Mouhadi K, Doufik J, Boujraf S.   +6 more
europepmc   +1 more source

New-Onset Gambling Addiction Following Treatment for Psychosis With Cariprazine. [PDF]

Cureus
Hashmi M, Nguyen A, Ilyas H.
europepmc   +1 more source

Tailoring cariprazine for dual disorders via secondary pharmacophore optimization. [PDF]

Eur J Med Chem
Vogt CD, Sanchez J, Bonifazi A, Saab E, Ranjit A, Rais R, Lane JR, Newman AH.   +7 more
europepmc   +1 more source

Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. [PDF]

Schizophr Bull
Hynes-Ryan C, Keating D, Carolan A, Brand B, Dazzan P, Gaughran F, Hahn M, Halstead S, Harrington SM, Hartnett Y, Kelleher I, Lyne J, McNicholas F, O'Connor K, Perry B, Sadowska E, O'Donoghue B, Sommer IE.   +17 more
europepmc   +1 more source

Third-Generation Antipsychotics as Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Narrative Review of Efficacy and Tolerability. [PDF]

Biomedicines
Rosso G, Peracchia S, Rizzo Pesci N, Di Salvo G, Maina G.   +4 more
europepmc   +1 more source

Editorial: Women with neuropsychiatric disorders: understanding & personalizing needs. [PDF]

Front Psychiatry
Barabássy Á, Dombi ZB, Gemzell-Danielsson K, Molnar MJ.   +3 more
europepmc   +1 more source

Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists. [PDF]

Ment Health Clin
Salwan A.
europepmc   +1 more source

Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor. [PDF]

Int J Neuropsychopharmacol
Ågren R, Sahlholm K.
europepmc   +1 more source